Lercamed

Lercanidipine, the active ingredient in Lercamed, is a dihydropyridine calcium channel blocker presented as an oral tablet for oral use. It is prescribed to lower elevated blood pressure in adults with hypertension and works by selectively relaxing vascular smooth muscle, improving arterial compliance and reducing systemic vascular resistance.

GNH USA supplies Lercamed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing and reliable distribution across global markets. The company adheres to stringent regulatory standards and provides comprehensive support for product registration and logistics.

Lercamed (lercanidipine) is used to manage high blood pressure by targeting the calcium‑channel pathway that controls vascular tone. - Essential hypertension: reduces both systolic and diastolic pressure in patients with primary hypertension. - Isolated systolic hypertension: helps control elevated systolic pressure, particularly in older adults. - Hypertensive patients with cardiovascular risk: contributes to overall blood pressure control as part of risk‑reduction strategies.

Lercamed may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Tachycardia - Fatigue

Serious or Rare Side Effects: - Angioedema - Severe hypotension - Myocardial infarction - Hepatic injury - Atrioventricular block - Allergic rash

When prescribing Lercamed, clinicians should consider several precautionary measures to ensure safe use. - Monitor blood pressure: check regularly after therapy initiation and dose adjustments. - Assess renal function: evaluate kidney status before starting and during treatment. - Avoid abrupt discontinuation: taper the dose to prevent rebound hypertension. - Caution in elderly: increased sensitivity to hypotensive effects may occur. - Pregnancy and lactation: use only if the potential benefit outweighs the unknown risk. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Lercamed can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Concomitant use with other antihypertensives: risk of excessive hypotension. - Grapefruit juice: can elevate drug levels and precipitate adverse events.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and volume status. - Beta‑blockers: observe for additive bradycardia or hypotension.